- Home
- CTLP vs ABUS Comparison
CTLP vs ABUS Comparison
Compare CTLP & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTLP
- ABUS
- Stock Information
- Founded
- CTLP 1992
- ABUS 2005
- Country
- CTLP United States
- ABUS United States
- Employees
- CTLP 358
- ABUS N/A
- Industry
- CTLP EDP Services
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- CTLP Technology
- ABUS Health Care
- Exchange
- CTLP Nasdaq
- ABUS Nasdaq
- Market Cap
- CTLP 776.5M
- ABUS 711.2M
- IPO Year
- CTLP N/A
- ABUS N/A
- Fundamental
- Price
- CTLP $10.58
- ABUS $4.67
- Analyst Decision
- CTLP Hold
- ABUS Strong Buy
- Analyst Count
- CTLP 4
- ABUS 2
- Target Price
- CTLP $12.00
- ABUS $5.00
- AVG Volume (30 Days)
- CTLP 721.1K
- ABUS 868.6K
- Earning Date
- CTLP 11-06-2025
- ABUS 11-06-2025
- Dividend Yield
- CTLP N/A
- ABUS N/A
- EPS Growth
- CTLP 473.33
- ABUS N/A
- EPS
- CTLP 0.86
- ABUS N/A
- Revenue
- CTLP $302,548,000.00
- ABUS $15,416,000.00
- Revenue This Year
- CTLP $18.25
- ABUS $138.02
- Revenue Next Year
- CTLP $12.30
- ABUS N/A
- P/E Ratio
- CTLP $12.30
- ABUS N/A
- Revenue Growth
- CTLP 12.64
- ABUS 53.23
- 52 Week Low
- CTLP $7.01
- ABUS $2.71
- 52 Week High
- CTLP $11.36
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- CTLP 43.02
- ABUS 60.99
- Support Level
- CTLP $10.55
- ABUS $4.26
- Resistance Level
- CTLP $10.61
- ABUS $4.76
- Average True Range (ATR)
- CTLP 0.05
- ABUS 0.20
- MACD
- CTLP 0.00
- ABUS 0.01
- Stochastic Oscillator
- CTLP 17.86
- ABUS 86.36
About CTLP Cantaloupe Inc.
Cantaloupe Inc is a technology leader powering self-service commerce by offering one integrated solution for payments processing, logistics, and back-office management. The group offers a comprehensive suite of solutions, including micro-payment processing, self-checkout kiosks, mobile ordering, connected point-of-sale (POS) systems, and enterprise cloud software. Its product and services portfolio consists of Card Readers, Self-Service Kiosks, Smart Coolers, Seed Pick Easy, Cantaloupe Go, Cheq, Smart Lock Connect, and Vine Digital Studio. The company derives revenue streams from subscriptions, transaction processing, and equipment sales.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.